Acute myeloid leukemia (AML) is the most common form of adult leukemia, and with an estimated five-year survival rate of 20%, the long-term prognosis for many patients is relatively grim.
“Current treatments for AML can initially reduce the number of AML cells to undetectable levels, a state referred to as ‘complete remission’,” says Fumihiko Ishikawa of the RIKEN Research Center for Allergy and Immunology in Yokohama. “Unfortunately, in a substantial proportion of these patients, AML eventually comes back—and many that relapse succumb to the disease.” The need for an improved arsenal to fight AML has guided much of Ishikawa’s work, and two recently published articles from his team present promising strategies for tackling this dreaded cancer.
AML originates in bone marrow, and relapse is initiated from small pockets of chemotherapy-resistant ‘leukemia stem cells’ (LSCs) within the marrow, which can be identified by their distinctive profile of cell-surface markers. In an effort to identify other features of LSCs that might offer useful therapeutic targets, Ishikawa, Yoriko Saito and team performed a thorough comparative analysis between LSCs and normal blood stem cells to identify genes with functional characteristics pertinent to cancerous growth whose expression is specifically elevated in LSCs1.
Their analysis revealed two candidate cell-surface proteins, CD25 and CD32; both of these are commonly overexpressed in chemotherapy-resistant LSCs, but can also be therapeutically targeted without negatively affecting blood cell development from healthy hematopoietic stem cells, making them potentially promising targets for thwarting relapse.
In parallel, Ishikawa and colleagues have also explored methods for boosting the efficiency of chemotherapy. Standard AML drugs such as cytosine arabinoside (Ara-C) work by targeting actively dividing cells, and LSCs are believed to elude chemotherapy by entering a quiescent, non-dividing state. The researchers hypothesized that LSCs could be made more vulnerable to Ara-C via simultaneous treatment with cytokines—naturally-occurring cell signaling molecules—that stimulate them into active division2. In fact, this two-pronged treatment led to a ten-fold increase in survival rate relative to chemotherapy alone for mice that had been transplanted with human LSCs.
Previous studies have suggested that despite some risk of toxicity, cytokine treatment is relatively safe for patients, and Ishikawa’s team is actively investigating the practicality and safety of interventions based on both of their recent discoveries. “We have been putting our best effort into the translation of these findings into medicine,” he says. “At the same time, we are continuing to try to identify unknown aspects of human AML and AML stem cells.”
The corresponding author for this highlight is based at the Research Unit for Human Disease Model, RIKEN Research Center for Allergy and Immunology
1. Saito, Y., Kitamura, H., Hijikata, A., Tomizawa-Murasawa, M., Tanaka, S., Takagi, S., Uchida, N., Suzuki, N., Sone, A., Najima, Y. et al. Identification of therapeutic targets for quiescent chemotherapy-resistant human leukemia stem cells. Science Translational Medicine 2, 17ra9 (2010).
2. Saito, Y., Uchida, N., Tanaka, S., Suzuki, N., Tomizawa-Murasawa, M., Sone, A., Najima, Y., Takagi, S., Aoki, Y., Wake, A. et al. Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML. Nature Biotechnology 28, 275–280 (2010).
gro-pr | Research asia research news
Scientists develop tiny tooth-mounted sensors that can track what you eat
22.03.2018 | Tufts University
NIH scientists describe potential antibody treatment for multidrug-resistant K. pneumoniae
14.03.2018 | NIH/National Institute of Allergy and Infectious Diseases
Satellites in near-Earth orbit are at risk due to the steady increase in space debris. But their mission in the areas of telecommunications, navigation or weather forecasts is essential for society. Fraunhofer FHR therefore develops radar-based systems which allow the detection, tracking and cataloging of even the smallest particles of debris. Satellite operators who have access to our data are in a better position to plan evasive maneuvers and prevent destructive collisions. From April, 25-29 2018, Fraunhofer FHR and its partners will exhibit the complementary radar systems TIRA and GESTRA as well as the latest radar techniques for space observation across three stands at the ILA Berlin.
The "traffic situation" in space is very tense: the Earth is currently being orbited not only by countless satellites but also by a large volume of space...
An international team of researchers has discovered a new anti-cancer protein. The protein, called LHPP, prevents the uncontrolled proliferation of cancer cells in the liver. The researchers led by Prof. Michael N. Hall from the Biozentrum, University of Basel, report in “Nature” that LHPP can also serve as a biomarker for the diagnosis and prognosis of liver cancer.
The incidence of liver cancer, also known as hepatocellular carcinoma, is steadily increasing. In the last twenty years, the number of cases has almost doubled...
In just a few weeks from now, the Chinese space station Tiangong-1 will re-enter the Earth's atmosphere where it will to a large extent burn up. It is possible that some debris will reach the Earth's surface. Tiangong-1 is orbiting the Earth uncontrolled at a speed of approx. 29,000 km/h.Currently the prognosis relating to the time of impact currently lies within a window of several days. The scientists at Fraunhofer FHR have already been monitoring Tiangong-1 for a number of weeks with their TIRA system, one of the most powerful space observation radars in the world, with a view to supporting the German Space Situational Awareness Center and the ESA with their re-entry forecasts.
Following the loss of radio contact with Tiangong-1 in 2016 and due to the low orbital height, it is now inevitable that the Chinese space station will...
Fraunhofer Institute for Organic Electronics, Electron Beam and Plasma Technology FEP, provider of research and development services for OLED lighting solutions, announces the founding of the “OLED Licht Forum” and presents latest OLED design and lighting solutions during light+building, from March 18th – 23rd, 2018 in Frankfurt a.M./Germany, at booth no. F91 in Hall 4.0.
They are united in their passion for OLED (organic light emitting diodes) lighting with all of its unique facets and application possibilities. Thus experts in...
A new scenario seeking to explain how Mars' putative oceans came and went over the last 4 billion years implies that the oceans formed several hundred million...
23.03.2018 | Event News
19.03.2018 | Event News
16.03.2018 | Event News
23.03.2018 | Life Sciences
23.03.2018 | Materials Sciences
23.03.2018 | Process Engineering